Skip to Main Content

Factitious hypoglycemia may be difficult to document. A suspicion of self-induced hypoglycemia is supported when the patient is associated with the health professions or has access to insulin or sulfonylurea medications taken by a diabetic member of the family. The triad of hypoglycemia, high immunoreactive insulin, and suppressed plasma C-peptide immunoreactivity is pathognomonic of exogenous insulin administration. Insulin and C-peptide are secreted in a 1:1 molar ratio. A large fraction of the endogenous insulin is cleared by the liver, whereas C-peptide, which is cleared by the kidney, has a lower metabolic clearance rate. For this reason, the molar ratio of insulin and C-peptide in a hypoglycemic patient should be less than 1.0 in cases of insulinoma and is greater than 1.0 in cases of exogenous insulin administration. When sulfonylureas, repaglinide, and nateglinide are suspected as a cause of factitious hypoglycemia, a plasma level of these medications to detect their presence may be required to distinguish laboratory findings from those of insulinoma.

Charlton  R  et al. Munchausen's syndrome manifesting as factitious hypoglycaemia. Diabetologia. 2001 Jun;44(6):784–5.
[PubMed: 11440375]
Hirshberg  B  et al. Repaglinide-induced factitious hypoglycemia. J Clin Endocrinol Metab. 2001 Feb;86(2):475–7.
[PubMed: 11157993]
Trenque  T  et al. Prevalence of factitious hypoglycaemia associated with sulphonylurea drugs in France in the year 2000. Br J Clin Pharmacol. 2002 Nov;54(5):548.
[PubMed: 12445037]

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.